| First Author | Nishimatsu H | Year | 1999 |
| Journal | Cancer Immunol Immunother | Volume | 48 |
| Issue | 1 | Pages | 56-61 |
| PubMed ID | 10235489 | Mgi Jnum | J:54519 |
| Mgi Id | MGI:1336429 | Doi | 10.1007/s002620050548 |
| Citation | Nishimatsu H, et al. (1999) CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo. Cancer Immunol Immunother 48(1):56-61 |
| abstractText | The CD95/CD95 ligand (CD95L) system plays an important role in the induction of lymphoid apoptosis and has been implicated in the suppression of immune responses. In this system, two murine CD95L-transfected renca clones and a control renca clone transfected only with the vector were implanted into the subcapsule of the left kidney of Balb/c and Balb/c nude mice. Both CD95L-expressing and control renca clones formed macroscopic tumors in all of the Balb/c and Balb/c nude hosts 14 days after implantation. Growth of tumors of murine CD95L-transfected renca cells was significantly better than that of control renca cells in Balb/c mice, while the growth advantage of CD95L transfectants was not observed in Balb/c nude mice. Lymphocytes underwent apoptosis mainly in the periphery of the CD95L-expressing tumors but not in control tumors grown in Balb/c mice, while lymphocytes undergoing apoptosis were not observed in CD95L-expressing tumors or in control tumors grown in Balb/c nude mice. Neutrophilic recruitment was rarely observed in CD95L-expressing or control tumors. CD95L expressed on renca cells possibly suppressed immune responses against renca tumors by inducing apoptosis of the infiltrating lymphocytes. However, CD95L-expressing renca cells did not form tumors in the renal subcapsule of allogeneic C3H/HeJ mice. |
